Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|January 14, 2014
Oncologists' Use of Twitter at Conferences
Author(s)Mike Thompson, MD, PhD
Mike Thompson, MD, PhD, from Stillwaters Cancer Support Services, discusses oncologists’ use of and attitudes towards Twitter.
Advertisement
Clinical Pearls
Mike Thompson, MD, PhD, from Stillwaters Cancer Support Services, discusses oncologists’ use of and attitudes towards Twitter.
- Thompson believes oncologists’ feelings towards social media have changed dramatically
- From 2011 to 2012, the growth in the number of Twitter users at ASH was small
- From 2012 to 2013, Twitter users at ASH increased from about 500 to about 1,200
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
4
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
5